Four‐Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI ‐52
Cancer Science · 2026
DOI: 10.1111/cas.70330 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Science, 2026. Verfasst von Jong-Seok Lee und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea. Hauptthemen laut MEDLINE: Bevacizumab, Nivolumab, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol Myers Squibb Foundation, Ono Pharmaceutical.
Themen: Onkologische Pflege
Abstract (Originalsprache)
In the Phase III TASUKI‐52 trial, nivolumab with carboplatin, paclitaxel (CP), plus bevacizumab significantly prolonged progression‐free survival (PFS), and resulted in longer overall survival (OS) in patients with advanced nonsquamous non‐small cell lung cancer (NSCLC). This final analysis evaluated 4‐year treatment outcomes in terms of OS, PFS and duration of response (DOR) by investigator assessment and safety, as well as the background characteristics and treatment courses associated with 4‐year survivors. Patients were randomized 1:1 to receive nivolumab ( n = 275) or placebo ( n = 275) in addition to CP plus bevacizumab. With a minimum follow‐up of 53.1 months, nivolumab with CP plus bevacizumab continued to show improvement in OS (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.58–0.88) and PFS (HR: 0.61; 95% CI: 0.50–0.74) compared to placebo with CP plus bevacizumab. The 4‐year OS rate was 34.7% in the nivolumab arm versus 22.1% in the placebo arm, and the 4‐year PFS rate was 13.7% in the nivolumab arm versus 3.3% in the placebo arm. Among 4‐year survivors, the median DOR was numerically longer in the nivolumab arm than in the placebo arm (34.7 vs. 13.5 months). No new safety signals were observed. Four‐year survival in the nivolumab arm was associated with the absence of bone metastases and age < 65, but not with PD‐L1 status and tumor size. In conclusion, treatment with nivolumab demonstrated long‐term survival benefit and durable response, which supports nivolumab with CP plus bevacizumab as a first‐line treatment option for advanced nonsquamous NSCLC. Trial Registration: ClinicalTrials.gov identifier: NCT03117049
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea.
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan.
- Department of Medical Oncology, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, South Korea.
- Division of Medical Oncology, Yonsei Cancer Center, Yonsei University, College of Medicine, Severance Hospital, Yonsei University Health System, Seoul, South Korea.
- Department of Pulmonary Medicine, Hamamatsu University Hospital, Hamamatsu, Shizuoka, Japan.
- Department of Thoracic Oncology, Aichi Cancer Center, Nagoya, Aichi, Japan.
ORCID-Profile: Shunichi Sugawara, Tatsuya Yoshida, Makoto Nishio, Yasushi Goto, Hiroaki Akamatsu, Kazuhiko Nakagawa
Förderung
- Bristol Myers Squibb Foundation
- Ono Pharmaceutical
Zitieren
APA
Lee, J. S., Sugawara, S., Kang, J. H., Kim, H. R., Inui, N., Hida, T., Lee, K. H., Yoshida, T., Tanaka, H., Yang, C. T., Inoue, T., Nishio, M., Goto, Y., Tamura, T., Yamamoto, N., Yu, C. J., Akamatsu, H., Takahashi, S., & Nakagawa, K. (2026). Four‐Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI ‐52. Cancer Science. https://doi.org/10.1111/cas.70330
Vancouver
Lee JS, Sugawara S, Kang JH, Kim HR, Inui N, Hida T, et al. Four‐Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI ‐52. Cancer Science. 2026. doi:10.1111/cas.70330
BibTeX
@article{Lee2026,
author = {Lee, Jong-Seok and Sugawara, Shunichi and Kang, Jin-Hyoung and Kim, Hye Ryun and Inui, Naoki and Hida, Toyoaki and Lee, Ki Hyeong and Yoshida, Tatsuya and Tanaka, Hiroshi and Yang, Cheng-Ta and Inoue, Takako and Nishio, Makoto and Goto, Yasushi and Tamura, Tomohide and Yamamoto, Nobuyuki and Yu, Chong-Jen and Akamatsu, Hiroaki and Takahashi, Shigeru and Nakagawa, Kazuhiko},
title = {Four‐Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI ‐52},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70330}
}
EUVIMED